Invention Grant
- Patent Title: HCV entry factor, Occludin
- Patent Title (中): HCV进入因子,Occludin
-
Application No.: US13122339Application Date: 2009-10-01
-
Publication No.: US08940960B2Publication Date: 2015-01-27
- Inventor: Alexander Ploss , Matthew Evans , Charles Rice
- Applicant: Alexander Ploss , Matthew Evans , Charles Rice
- Applicant Address: US NY New York
- Assignee: The Rockefeller University
- Current Assignee: The Rockefeller University
- Current Assignee Address: US NY New York
- Agency: Thompson Coburn LLP
- Agent Charles P. Romano
- International Application: PCT/US2009/059285 WO 20091001
- International Announcement: WO2010/040001 WO 20100408
- Main IPC: C12N15/90
- IPC: C12N15/90 ; C12N15/63

Abstract:
The human Occludin protein is identified as an essential Hepatitis C Virus (HCV) cell entry factor. Occludin is shown to render murine and other non-human cells infectable with HCV and to be required for HCV-susceptibility of human cells. Associated methods for inhibiting HCV infection, transgenic animal models for HCV pathogenesis, methods of identifying compounds or agents that prevent or mitigate interaction of HCV with Occludin, and HCV inhibitory agents are also disclosed. Kits and cell culture compositions useful for identifying compounds or agents that prevent or mitigate interaction of HCV with Occludin are also provided.
Public/Granted literature
- US20110271356A1 HCV ENTRY FACTOR, OCCLUDIN Public/Granted day:2011-11-03
Information query
IPC分类: